about
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesisIn Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell typePrognostic relevance of CCN3 in Ewing sarcomaMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugGenome-wide association study identifies two susceptibility loci for osteosarcomaCommon variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcomaElevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.From a 16th century monastery to a 21st century orthopaedic hospitalChordoma of the mobile spine: fifty years of experience.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.Difficulty distinguishing benign notochordal cell tumor from chordoma further suggests a link between them.Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progressionSorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.Enchondroma vs. chondrosarcoma: a simple, easy-to-use, new magnetic resonance sign.Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysisMolecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators.CD99 acts as an oncosuppressor in osteosarcomaOsteosarcoma (osteogenic sarcoma).Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution.CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis.Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four yearsPrognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution.p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expressionMethylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of boneIntegrated approaches to miRNAs target definition: time-series analysis in an osteosarcoma differentiative model.A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with OsteosarcomaSurvival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
P50
Q24642797-A504BA4F-A05E-477E-AC07-3B249711C17FQ28244685-27CF1DE4-F10B-466D-A46F-B4164038F4AEQ28255834-DBB81909-533B-4859-AEA8-616151BF458BQ28538155-A3827A93-4D7E-4ACE-AEE1-B8FE919074E7Q28659642-1187EA29-A739-4736-90DB-A3B9C62FC638Q29028729-FD642CD4-ED2E-421C-B860-EECC48C936DBQ30439048-22237350-6838-4134-9D47-B599DBD85B06Q30988491-E308560E-FA0F-479C-8996-724AF9155E8EQ33267438-4BC2E812-157D-4B37-A64A-5B14E612DC22Q33272488-CE5619E2-3911-41B8-B3A5-DF884F22E554Q33273555-A0DA7278-27CD-4250-AA5C-E375B481A3BDQ33275511-85502C47-74CA-46F0-A655-AF451AB91AE3Q33369033-FC49DD1F-B6B5-4B0D-9F38-3A330FBA1EFFQ33382768-C147A8F4-994E-42DC-8161-B57B3EABCB02Q33407709-C9716377-A881-4CB8-8BA3-F612BC81C30CQ33419286-20A13FBC-F577-40C9-99F6-AF8BA645CB06Q33520381-CF8616A9-3C88-4CC9-8C33-2AF64E8EB426Q33582914-F3A36F01-D88E-4D2B-9AF3-0C2970CDAFC4Q33881163-31C2DBFE-BB2F-4DB3-909B-5BDE21189A38Q34121295-49EEF6B1-BDBD-46A5-968E-DBB6A27CC91DQ34159317-E5C8B21C-A5DE-4714-8A35-25C0A8A7B574Q34226841-3BE0E0A0-0637-4823-B011-8E67CD67B460Q34325539-6A626102-3C0A-4C2C-A086-E7570C59DD19Q34483649-5077019E-86BF-4282-B0B6-5226F99BD604Q34574274-96FE7627-6B0D-4A17-868E-156BB7D2D4FAQ34607877-55022CED-0CAE-4004-99E0-99B6566D11FAQ34629236-3564A1EF-E3E3-4657-BE3F-27B348920ADDQ34633416-107C6567-63E6-4E73-A1A2-2D0BEB51D679Q34638074-B4D1E5C0-83D4-4DF0-93D3-83F58A230959Q34755599-5D1A7720-C8AB-458F-BE44-2690B93921AAQ34801108-ECCEDE98-8A8E-4F45-B0E3-6397548190FEQ35061368-614841E7-445F-4948-811E-D28828799CBAQ35103838-BD560DA7-64B3-409D-8562-E5D0E3C0B0ECQ35212194-CCBFBADB-5725-4E51-8E34-383A10271DD4Q35503066-140B8FC4-C5B1-487A-B372-35A9E99DA75EQ35558868-C1C8C479-BAE4-4D4F-A9AA-7E5FDBE28BBFQ35560747-70EC16A1-B7F0-49B6-A906-842BB632B505Q35678071-F36502DB-24D3-4C22-B271-BBCAE2D88C5DQ36029709-A49D8375-0AAF-40E0-B100-22D5B576B21BQ36544082-5790B973-708A-4FF5-842A-985140DD621F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Piero Picci
@ast
Piero Picci
@en
Piero Picci
@es
Piero Picci
@nl
Piero Picci
@sl
type
label
Piero Picci
@ast
Piero Picci
@en
Piero Picci
@es
Piero Picci
@nl
Piero Picci
@sl
prefLabel
Piero Picci
@ast
Piero Picci
@en
Piero Picci
@es
Piero Picci
@nl
Piero Picci
@sl
P1053
J-5979-2016
P106
P1153
7102271842
P21
P31
P3829
P496
0000-0002-8519-4101